In Support of CDK4/6 Inhibitors—A Meta-analysis of Available Randomized Data
A partir d'une revue systématique de la littérature (9 études, 5 043 patientes), cette méta-analyse évalue l'efficacité, du point de vue de la survie globale, de la survie sans progression et du taux de réponse objective, et la toxicité de l'ajout d'inhibiteurs de CDK4/6 à une thérapie endocrinienne chez des patientes atteintes d'un cancer du sein HR+ ERBB2- de stade métastatique
The recent development of inhibitors of cyclin dependent kinases 4 and 6 (CDK4/6) is arguably one of the most clinically important discoveries for patients living with hormone receptor (HR)–positive, ERBB2 (formerly HER2)–negative metastatic breast cancer. Currently, there are 3 available CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. These CDK4/6 inhibitors induce cell cycle arrest by preventing the G1 to S phase transition, and they are often administered in combination with endocrine therapy (ET). Li et al performed a meta-analysis of the 9 published randomized clinical trials that compared ET plus either a CDK4/6 inhibitor or placebo. Eight phase 3 clinical trials were included as well as 1 randomized phase 2 study. Phase 1 trials, retrospective studies, and those without overall survival (OS) outcomes were not included in their analysis. The authors sought to analyze the potential benefit of CDK4/6 inhibitors with regard to OS, progression-free survival (PFS), overall response rate, and development of adverse events.
JAMA Network Open , commentaire, 2019